Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial

Overview of attention for article published in Frontiers in immunology, May 2021

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 17 news outlets

twitter: 3 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 23 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 3 X posts from 3 X users, with an upper bound of 1,119 followers.

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial https://t.co/eq6YBDUdCb

15 Jun 2021

Reply Repost Favourite

Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial https://t.co/k9meibpqID

29 May 2021

Reply Repost Favourite

New article: Combining a Universal Telomerase Based Cancer Vaccine With Ipilimumab in Patients With Metastatic Melanoma - Five-Year Follow Up of a Phase I/IIa Trial https://t.co/vlYdD8nrMQ #melanoma #oncology https://t.co/fZsQCoVz0m

28 May 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.